Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...
In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...
Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...
News-Medical.Net on MSN21h
Alzheimer's-modifying drug lecanemab's effectiveness may vary between gendersSince becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...
The U.S. Environmental Protection Agency (EPA) is reviewing several key emissions regulations that could impact the trucking ...
DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...
Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...
Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback